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Visceral pain is experienced by 40% of the population, and 28% of cancer patients suﬀer from pain arising from intra- abdominal
metastasis or from treatment. Neuroanatomy of visceral nociception and neurotransmitters, receptors, and ion channels that
modulate visceral pain are qualitatively or quantitatively diﬀerent from those that modulate somatic and neuropathic pain.
Visceral pain should be recognized as distinct pain phenotype. TRPV1, Na 1.8, and ASIC3 ion channels and peripheral kappa
opioid receptors are important mediators of visceral pain. Mu agonists, gabapentinoids, and GABAB agonists reduce pain by
binding to central receptors and channels. Combinations of analgesics and adjuvants in animal models have supra-additive
antinociception and should be considered in clinical trials. This paper will discuss the neuroanatomy, receptors, ion channels,
and neurotransmitters important to visceral pain and provide a basic science rationale for analgesic trials and management.
1.Introduction
Normal individuals do not perceive signals emanating from
their intestinal tract; however, enteric and extrinsic visceral
aﬀerents become hypersensitive in pain-processing disorders
such as functional bowel syndromes or in diseases associated
with inﬂammation such as inﬂammatory bowel disease
and pancreatitis. Both inﬂammatory bowel disease and
cancer-related metastases to viscera may produce persistent
pain despite resolution of the underlying disease state [1].
Unexplained abdominal pain accounts for 40% of gastroen-
terology practice in the United Kingdom. Most abdominal
pain is due to functional gastrointestinal disorders; irri-
table bowel syndrome, and functional dyspepsia [2]. Ten
to 40% of the normal population will have complaints
of abdominal cramps or pain. Most use over-the-counter
medications usually antispasmodics and or antacids [3].
Inﬂammatory bowel disease causes visceral hypersensitivity,
intestinal stenosis, anorectal urgency, ﬁstula, and abscess.
One-third to half of individuals with inﬂammatory bowel
will have disabling visceral symptoms such as pain or colic or
symptoms that resemble the irritable bowel syndrome [4, 5].
IndividualswithCrohn’sdiseaseinremissionfrequentlyhave
i r r i t a b l eb o w e ls y n d r o m es y m p t o m sa sar e s u l to fp e r s i s t e n t
visceral hypersensitivity which may mislead both patients
and clinicians to believe that the Crohn’s disease is active
[6–9].Hence,distinguishingfunctionalfromorganicvisceral
pain can be a challenge. The duration of pain is longer
with functional bowel disorders, whereas organic etiologies
produce nocturnal pain and are frequently associated with
weight loss and constitutional symptoms [3].
Visceral pain accounts for 28% of cancer-related pain. It
is often accompanied by other pains such as neuropathic or
somatic pain. Visceral pain in cancer patients may also be
the result of treatment complications or comorbid diseases
[10]. Causes of cancer-related visceral pain include hepatic
metastases with extension to the hepatic capsule, biliary
obstruction, pancreatitis as well as pancreatic primaries and
peripancreatic nodal enlargement, retroperitoneal adenopa-
thy from metastases, and visceral organ obstruction such as
small bowel or colon obstruction, mesenteric inﬁltration,
and peritoneal implants of cancer. Complications include
not only intestinal obstruction by perforation and intus-
susceptions, but also visceral pain is described as pressure-
like, intermittently squeezing or cramp, not well localized,
vague in character, and diﬃcult for patients to describe.2 Pain Research and Treatment
Table 1: Distinctive features of visceral spinal aﬀerents relative to somatic.
(1) Dual extrinsic aﬀerent system
(2) Convergence of aﬀerents on somatic and other visceral aﬀerents within the spinal cord
(3) Widely overlapping receptive ﬁelds
(4) Dichotomization of ﬁbers where a single neuron innervates two viscera
(5) Collateral activation of autonomic and enteric nervous system
(6) Larger cell bodies within dorsal root ganglia
(7) Wide overlapping receptor ﬁelds
(8) Lack of specialized nerve terminals
(9) First-order aﬀerents arborize over several spinal segments
(10) Greater expression of transient receptor potential (TRPV1), sodium (Na 1.8), acid (ASIC3) ion channels, and calcitonin
gene-related protein (CGRP)
(11) Limited number of stimulus responses (distension, ischemia, and inﬂammation)
(12) More discrete location of ﬁrst-order terminals within the spinal cord (superﬁcial dorsal horn, lamina V, and central)
(13) Aﬀerents ascend with parasympathetic and sympathetic neuronal projections
(14) Viscerovisceral hyperalgesia and hypersensitivity
(15) Visceromotor responses and referred pain to somatic sites innervated by the samespinal cord level
(16) Second-order aﬀerents ascend in the dorsal column
(17) Nonsomatotopically arranged input in dorsal column and central lateral thalamus unlike the lateral spinothalamics
(18) Poor representation in S1 cortex
(19) Greater emotional and autonomic responses to pain than somatic pain
Visceralpainisfrequentlyaccompaniedbynausea,vomiting,
and sweating. Pain, particularly if severe, is often referred
to distant somatic (superﬁcial) sites [11]. Treatment recom-
mendations for visceral pain have been the same for somatic
pain, yet visceral pain processing is distinctly diﬀerent from
somaticnociceptionandasaresultshouldperhapsbetreated
diﬀerently from somatic pain (Table 1).
2.Neuroanatomy
2.1. Vagus Innervation. This sensory system of the gastroin-
testinal tract consists of intrinsic (enteric) sensory aﬀerents
andextrinsic(vagus,spinal,andpelvic)aﬀerents.Theintrin-
sic system functions independently of the CNS. Neurons
are directly exposed mechanical forces and the chemical
environment which is unlike somatic aﬀerents neurons.
Enterochromaﬃn cells within the mucosa and enteroen-
docrine cells release serotonin, cholecystokinin, orexin, and
leptin which modulates and regulates motor activity [12].
The submucosal enteric plexus and myenteric plexus have
a high degree of synaptic interactions which can be either
inhibitory or stimulatory for the purpose of regulating gas-
trointestinal motility and peristalsis. Both plexuses received
inputfromparasympatheticandsympatheticeﬀerents.Vagal
aﬀerents are largely made up of neurons which interact with
the submucosal and myenteric plexus and allow “crosstalk”
between intrinsic and extrinsic systems [12]. The intrinsic
system contains ganglia and interstitial cells of Cajal which
act as pacemakers and gauges for muscle tension. Certain
ion channels such as the transient receptor potential (TRP)
group of ion channels which have a major role in pain
processing are not found on intrinsic enteric neurons [12].
The vagus receives input largely from the mucosa and
muscle enteric aﬀerents as do the pelvic extrinsic aﬀerents.
Cell bodies of the vagus are found in the jugular and nodose
ganglia; both ganglia are morphologically, biochemically,
and functionally diﬀerent from one another. Expression of
ion channels and signal transduction are distinctly diﬀer-
ent between the two ganglia [12]. Vagal sensory aﬀerents
outnumber eﬀerents 10 to 1 in both ganglia. Both project
to the nucleus tractus solitarius [13]. From the nucleus
tractus solitarius, second-order aﬀerents project to the
parabrachial nucleus and thalamus. Vagal neurons process
physiologic information such as the nature and content
of luminal constituents and presence or absence of motor
activity and in response generate nonpain but potentially
noxious symptoms such as nausea, vomiting, and early
satiety [13]. Vagal aﬀerent terminals are found in close
proximity to enterochromaﬃn cells and are responsive to
regional serotonin by way of certain serotonin (5HT1 5HT 3,
5HT4, and 5HT7) receptors. Ghrelin, released from gastric
endocrine cells, binds to receptors on the vagus and nodose
ganglia. Ghrelin blocks mucosal and muscle enteric aﬀerents
whicharemechanicallysensitive inﬂuencing motility, satiety,
gastric emptying, and proximal stomach relaxation. The
subjective result is increased appetite and meal volume
[14, 15]. Stomach distention, cholecystokinin, and leptin
(which bind to receptors on the vagus and nodose ganglia)
produce satiety and reduced nutritional intake [16–18]. Also
found on intrinsic enteric neurons are mu and kappa opioid
receptors. Activation of mu receptors inhibits peristalsis,
stimulates circular muscle segmentation, reduces intralumi-
nal secretion, and increases ﬂuid absorption from the bowel
lumen [19, 20]. The use of mu agonists for visceral pain willPain Research and Treatment 3
therefore have an adverse eﬀect on gastrointestinal motility
and may increase patient symptom burden. Vagus muscle
mechanicoreceptorsarelowthresholdwhichelicitmaximum
ﬁring rates within physiologic distention pressures and diﬀer
from extrinsic spinal aﬀerents [21]. The mechanicoreceptors
consist of “in-series-tension” receptors between longitudinal
and circular muscle and intraganglionic laminar endings
which are intimately arrayed around enteric ganglia. Both in
series-tension receptors and laminar endings contain nonen-
capsulated low-threshold sensors with primitive endings
responsive to nonnoxious physiologic stimuli [12, 21, 22].
2.2. Spinal Aﬀerents. Extrinsic spinal visceral aﬀerents locat-
ed in the serosa and mesentery ascend to the thoracolumbar
dorsal root ganglia with parasympathetic and sympathetic
ﬁbers [21]. A large battery of pain mediators (protons,
prostaglandins, interleukins anti-inﬂammatory cytokines,
and bradykinin) are released as a result of visceral inﬂam-
mation, hollow organ distention or distortion, and ischemia.
These mediators bind to various ion channels or recep-
tors found on spinal aﬀerents. Certain channels such as
the transient receptor potential ion channels (TRP), acids
sensing ion channels (ASIC), and sodium channels (Na)
are activated resulting in an action potential. Hence, spinal
visceral aﬀerents have promiscuous chemosensitivity [13,
21, 23]. Visceral spinal aﬀerents have a distinctive large cell
body relative tosomatic aﬀerentsvisualized within the dorsal
root ganglia. Visceral aﬀerents makeup 7% of sensory cell
bodies within the dorsal root ganglion [13, 23]. A signiﬁcant
proportion of visceral spinal aﬀerents are high-threshold
or silent nociceptors which respond selectively to noxious
stimuli. Spinal visceral aﬀerent action potentials propagate
centrifugal and centripetal along collaterals resulting in the
release of neurotransmitters, mainly calcitonin gene-related
protein (CGRP) and substance P (SP) from varicose nerve
terminals which in turn modulate blood ﬂow and enteric
motor reﬂexes; the end result is a neurogenic inﬂammatory
response [13, 23]. Visceral spinal aﬀerents converge on
somatic aﬀerents within the dorsal root ganglia and dorsal
horn which is thought to be the mechanism for somatic
referred pain [24, 25]. Convergence also occurs among
visceral aﬀerents within the same dorsal horn segment
resulting in a viscerovisceral convergence and hyperalgesia
[25]. In animal models, visceral pain causes a visceromotor
responseobservedinanteriorabdominalwallmusculatureas
ar e s u l to fc o n v e r g e n c ew h i c hi su s e da sa no b j e c t i v em e a s u r e
of nociception. This can be elicited by experimental colitis,
acetic acid peritonitis, or colorectal distention. Visceral con-
vergence leads to cross-organ sensitization in which disease
in one visceral organ increases the pain arising from another
visceralorganinnervatedbythesamespinalsegment[22,24,
25]. As an example, in mice and rats, experimental colitis
increases bladder sensitivity and contractions [26]. Clinical
individuals with irritable bowel syndrome have a greater
incidence of urinary bladder sensitivity compared with the
normal population [27]. Another mechanism proposed for
viscerovisceral sensitivity is dichotomized sensory ﬁbers in
which one aﬀerent neuron innervates two visceral organs
[28, 29]. Another proposed mechanism is generation of
retrograde action potentials via viscerovisceral convergence
leading to upregulation of neurotransmitters and ion chan-
nels in the second visceral organ [30, 31]. Finally, visceral
aﬀerents travel with parasympathetic and sympathetic ﬁbers
which activate aﬀerents within autonomic ganglia by way of
collaterals resulting in an autonomic and motor response
in the second visceral organ [32]. Spinal visceral aﬀerents
have large overlapping receptive ﬁelds relative to somatic
aﬀerents and sparse innervation relative to somatic tissues.
Because of the anatomical diﬀerences and convergence,
visceral pain is poorly localized, diﬀuse, and frequently
identiﬁed by its somatic referral pattern. Viscerovisceral
hypersensitivity can lead to diagnostic dilemmas as to where
the pathology is occurring or misdiagnosis of the origin
of visceral pain [12]. Somatic convergence can lead to
inhibitory or excitatory responses. A counterirritation can
produce an inhibitory response at either somatic or visceral
site.Inhibitoryresponsesfromconvergencecanlastaslongas
onesecondandmayaccountforthecolickynatureofvisceral
pain [33]. Patients often use counterirritation at referred
somatic sites that reduce visceral pain [33].
Second-order visceral aﬀerents ascend the thoracolum-
bar spinal cord through the dorsal column to gracile and
cuneate nuclei. As a result, an anatomical cervical midline
myelotomy interrupts dorsal column secondary aﬀerent
neurotransmission and reduces visceral pain and nocifensive
responses in animal with pancreatic and duodenal pain [34–
36].Third-orderaﬀerentsascendtotheventralposterolateral
and central lateral nucleus of the thalamus [37, 38]. The cen-
trallateralnucleusisthemajorsiteformedialaﬀerentstraﬃc
important to emotive pain responses. Visceral aﬀerents are
highly represented in the medial pain matrix (insular cortex,
prefrontal cortex, and anterior cingulate gyrus) which is
responsible for the large emotional response to visceral pain.
VisceralaﬀerentsaresparselyrepresentedinS1cortex;hence,
visceral pain is poorly localizable by patients. The anterior
cingulate gyrus is critical to downward modulating pain
through the periaqueductal gray and rostral ventromedial
medulla (RVM) [39]. The RVM has been demonstrated
to exert descending facilitatory inﬂuences in visceral pain
process and is a critical compound to the maintenance of
pain from visceral inﬂammation [40, 41].
3.ImportantChannels,Receptors,and
MediatorsofVisceral Pain
Several channels are important to visceral pain: transient
receptor potential vanilloid-1 (TRPV-1), ASIC3 channels
and sodium channels (Na) particularly those that are
tetrodotoxin resistant (NA 1.8 and 1.9), and calcium chan-
nels. Certain receptors downmodulate pain: the gamma
aminobutyric acid-B (GABA-B) channels, kappa and mu
opioidreceptors,andsomatostatinreceptors.Thesechannels
and receptors are potential targets for novel analgesics to
treat visceral pain.
3.1. Transient Receptor Potential Ion Channels. The TRP
family of ion channels is TRPV1, TRPV2, TRPV3, TRPV4,4 Pain Research and Treatment
TRPM 8, and TRPA1. These channels are, in general, ther-
moreceptorsfoundonpoorlymyelinatedandnonmyelinated
aﬀerentsarisingfromthedorsalrootganglia,nodoseganglia,
and the CNS [42–46]. TRP channels also respond to
nonnoxious heat (TRPV3, TRPV4, and TRPM8), capsaicin
(TRPV1), methanol (TRPM8) camphor (TRPV3), mustard
(TRPA1), protons (TRPV1) and the endogenous cannabi-
noid, and anandamide (TRPV1) [46]. These channels are
calcium permeable, nonselective channels with 4 identical
subunits and a central pore. Each subunit consists of a 6
transmembrane (TM) segments with an amphipathic region
between TM5 and TM6 that allows cations through. The
cytoplasmic N and C terminal tail of the subunits can
be modulated by various kinases through phosphorylation.
Phosphorylation inﬂuences channel endocytosis and expres-
sion. Chemical activators may be direct channel activators
or may allosterically modify channels to reduce conduction
thresholds [46, 47]. The TRP family is subject to multiple
single-nucleotide polymorphisms which inﬂuence channel
activation. These channels are posttranslationally modiﬁed
by multiple kinases: protein kinase A, protein kinase C,
calcium calmodulin kinase II, and the tyrosine kinase src
which prevents channel internalization and desensitization,
amplifying channel conductance. Multiple pain mediators
(certain inﬂammatory cytokines (ILB), bradykinin, pro-
teases, and ATP) stimulate kinase activation and channel
phosphorylation [46, 48, 49].
TRPV1 channels are highly expressed on visceral spinal
aﬀerents and colocalize with nerve growth factor recep-
tor (trk-A). They are selectively expressed on peptidergic
neurons (neurons which express CGRP and SP) [42, 45].
TRPV1-activated aﬀerents release inﬂammatory peptides
(CGRP and SP to produce neurogenic inﬂammation, glu-
tamate. TRPV1 plays a signiﬁcant role in gastrointestinal
inﬂammation, hypersensitization, but also function [50–52].
TRPV1 is expressed in bladder aﬀerents and plays a role
in micturition as well as pathologic states of interstitial
cystitis [53]. Inﬂammatory states such as Crohn’s colitis
upregulate TPRV1 through kinases. Nerve growth factor
and prostaglandins upregulate TRPV1 through the same
mechanism [54–57]. TRPV1 has been demonstrated to be
upregulated in upper gastrointestinal disorders such as gas-
troesophagealreﬂuxdiseaseandpancreatitis[58,59].TRPV1
remains upregulated not only in those with inﬂammatory
bowel disease in remission but also with irritable bowel type
symptoms [60]. TRPV1 is also upregulated in the CNS;
inhibitors in development may need to cross the blood-brain
barrier to be fully eﬀective [45].
TRPA1 is highly expressed on primary visceral aﬀerents
and is important in visceral hypersensitivity [61]. TRPA1 is
upregulated in experimental colitis and deletion of TRPA1
expression in a mouse gene “knocke-out” model reduced
colitis-induced mechanical hypersensitivity [62].
3.2. Acid Sensing Ion Channels. ASIC family of ion channels
is directly gated by protons as “chemoelectrical transducers.”
Tissueacidosiswithischemia,fractures,tumor,andincisions
a c t i v a t e sA S I C sa tap Hb e l o w7 . 4 ,p a r t i c u l a r l yb e l o w7 . 0[ 63,
64]. ASIC undergoes sustained depolarization with tissue
acidosis resulting in nonadapting pain [63–65]. The channel
structure consists of 6 subunits derived from 4 diﬀerent
genes. Each subunit is identiﬁed by the intracellular C and
extracellular N terminus amino acid composition (ASIC 1a,
1 b ,2 a ,2 b ,3 ,a n d4 )[ 66]. Each subtype has 2 hydrophobic
transmembrane domains which ﬂank a large extracellular
loop. Although ASIC channels mainly gate protons, they
are also permeable to sodium. ASIC subtypes form channel
dimers which inﬂuence channel expression. Homomeric
ASIC 1a dimers conduct calcium [66]. Subtypes 1, 2, and 3
are expressed on intrinsic enteric neurons, and subtypes 3
are particularly expressed on spinal extrinsic aﬀerents [67–
69]. ASIC3 is up-regulated by inﬂammatory cytokines, metal
ions, and certain neuropeptides (FMRT amide) [70]. Such
neuropeptides are increased in the spinal cord and dorsal
root ganglia with visceral inﬂammation. The endogenous
kappa opioid receptor agonist, dynorphin, enhances ASIC
activity and prevents desensitization [64]. Nonsteroidal anti-
inﬂammatory drugs (NSAIDs) such as diclofenac inhibit
ASIC3. Toxins from the spider, Psalmopoeus cambridgei,a n d
the sea anemone, Anthopleura elegantissima, contain ASIC
inhibitors. The potassium sparing diuretic, amiloride, also
inhibits multiple ASIC subtypes [71–74].
ASIC channels are more important to visceral mechan-
icoreceptors sensory function than cutaneous aﬀerent func-
tion [69, 75]. ASIC3 is also an important mediator of cardiac
pain from coronary ischemia, cough, and bronchospasm
from airway acidiﬁcation [76, 77].
3.3. Voltage-Gated Sodium Channels. Sodium-gated chan-
nels can be divided into those which are tetrodotoxin
sensitive (Na 1.1–1.7) and resistant (Na 1.8 and 1.9) [78].
Tetrodotoxin-resistant channels and Na 1.7 are mainly
expressed on nociceptor sensory aﬀerents [79]. These mem-
brane glycoproteins have large alpha subunits and smaller
beta subunits which form 9 recognizable subsets [80]. These
channels have 4 domains made up of individual 6 trans-
membrane segments (S1-6). The sodium pore is between
the ﬁfth and sixth segments. Na 1.8 is the most important
sodium channel visceral pain and hypersensitivity [80–
82]. In experimental colitis, Na 1.8 expression is increased
threefold in dorsal root ganglia within that T 9-13 segment
of the mouse. There appears to be a selective expression of
this channel and not other sodium channels [83, 84]. Na
1.8 channels are also important to bladder hypersensitivity
caused by chemical irritants in experimental animals. Na
1.8 is not important to pain of pancreatitis [85, 86]. In the
gene “knock-out” (Na 1.8 null) mouse model, experimental
jejunitis failed to produce the expected hypersensitivity
as measured by visceromotor responses [81, 82]. Both
nerve growth factor and prostaglandins (PGE2) increased
expression of tetrodotoxin-resistant sodium channels [87–
89]. As a result, NSAIDs indirectly block sodium channel
neurotransmission by preventing PGE2-induced upregula-
tion of sodium channels [89]. Sodium channels can be
up-regulated by phosphorylation of their intracellular C
terminus [90, 91]. There are no selective Na 1.8 inhibitors
which could potentially target visceral pain. There are aPain Research and Treatment 5
group of peptides, (conotoxins) that are a source of sodium
channel blockers being developed, one of which has been
approved for spinal analgesia [92].
3.4. Voltage-Gated Calcium Channels. Voltage-gated calcium
channels have an alpha-1 subunit which forms the channel
pore and alpha-2 delta subunit which facilitates alpha-1
traﬃct om e m b r a n es u r f a c e s[ 93]. There are 10 diﬀerent
alpha-1 subunits and 4 alpha-2 delta subtypes. Alpha-2 delta
subtypes 1 and 2 bind pregabalin and gabapentin. Subtype
1 is found within the medial pain matrix (anterior cingulate
gyrus, insular cortex, and amygdala) [94, 95]. Alpha-2 delta
subunit 1 is also expressed within the dorsal root ganglia,
spinalcord,andsmoothmuscleofthesmallbowelassociated
with N-type calciumchannels [94]. Subtype 2 is found in the
periaqueductal gray, spinal cord, and diﬀusely throughout
the CNS but not in colon or small bowel smooth muscle
[95, 96]. Pregabalin and gabapentin bind to alpha-2 delta
subunits in the cytoplasm and prevent expression of calcium
channels on membranes [97, 98]. By binding and preventing
expression, calcium conduction is blocked, and SP, CGRP,
and glutamate cannot be released from primary aﬀerent
neurons [93]. Prevention of neurotransmitter release by
pregabalin and gabapentin occurs only in pathologic states
when calcium channels are being up-regulated and activated
[99, 100]. Pregabalin and gabapentin are predominantly
central acting analgesic [101–103]. Gabapentinoids have
been shown to reduce visceral hypersensitivity in exper-
i m e n t a la n i m a l sa sw e l la ss y m p t o m so fi r r i t a b l eb o w e l
s y n d r o m ei nh u m a n s[ 104–109]. Low-dose gabapentin and
morphine reduced writhing in rats given intraperitoneal
acetic acid at doses which were found to be ineﬀective
as single agents [110]. Not only do gabapentinoids reduce
nociceptive neurotransmission centrally but also improve
bowel compliance to distention perhaps through blocking
alpha-2 delta subunits in smooth muscle [105, 111].
Other calcium channels may also be involved in vis-
ceral hypersensitivity. Activation of T-type calcium channels
subtype Ca (v) 3.2 on primary spinal visceral aﬀerents
has been associated with irritable bowel-like symptoms in
an animal model. Symptom behaviors resolved when T-
type calcium channels were blocked [112]. In experimental
bowel ischemia, mesenteric aﬀerent neurotransmission was
blocked by the L-type calcium channel blocker nifedipine
[113].
3.5. Opioid Receptors. Kappa and mu opioid receptors are
found on visceral aﬀerents [114–116]. Distribution along
the gastrointestinal tract indicates that endogenous opiate
peptides have a modulating function for both gastrointesti-
nal motility and secretory function. Constipating eﬀects
and dysmotility with morphine is predominantly due to
actions on intrinsic enteric neurons [117]. Kappa receptors
have little adverse eﬀect on gastrointestinal motility, but
doses are limited by central toxicity such as dysphoria
[118–120]. The central toxicity of mu receptor agonists
includes confusion, myoclonus, nausea, and vomiting which
limits titration and adds symptom burden to patients with
visceral pain [118]. In addition, certain mu opiates such
as the enkephalin derivative DAMGO stimulate mesenteric
aﬀerents action potentials which are blocked by the opioid
receptor antagonist alvimopan [121]. Mesenteric aﬀerents
respond with increasing ﬁring rate when exposed to mu
and delta receptor agonists which does not occur with
selective kappa receptor agonists [122, 123]. Morphine has
been shown to increase the visceral hypersensitivity and
viscerosomatic referral in animal models of colitis and
irritable bowel syndrome (caused by butyrate) [124].
There are 3 subtypes of kappa receptors which inhibit
aﬀerent ﬁring and visceromotor responses to noxious col-
orectal distention in animal models [125–129]. In these
animal models, antinociception occurs without change in
colon muscle compliance [125]. Kappa opioids in animal
models reduced inﬂammation (colitis)nociceptive responses
[130–132]. Kappa receptor gene “knocked-out” mice display
increasing writhe to acetic acid peritonitis compared with
wild-type mice [133]. The kappa receptor agonist, CR 66,
in humans selectively reduced visceral pain by esophageal
distention pain tolerance but reduced somatic pain thresh-
olds as measured by cutaneous pain [134]. Kappa receptors
are important modulators of visceral pain, and it is the
peripheral kappa receptor not the central receptor which is
important in contradistinction to mu receptor agonists.
Kappa receptors are also found on the vagus and nodose
ganglia. The kappa agonist, asimadoline, has been reported
to reduce satiety and enhance postprandial gastric volumes
[135, 136]. Asimadoline has no inﬂuence on motility. Asi-
madoline reduced pain in a group of patients with irritable
b o w e ls y n d r o m e[ 136]. However, “on-demand” asimadoline
was not eﬀective in reducing irritable bowel symptoms and
worsened symptoms in diarrhea prone patients [137]. A
second peripheral-restricted kappa receptor agonists, fedo-
tozine, reduced nociceptive reﬂexes triggered by gut disten-
tion and reduced pain related to irritable bowel syndrome
and nonulcer dyspepsia [138]. Fedotozine reversed ileus
caused by acetic acid peritonitis in rats and prevented c-fos
expression in the spinal cord, a measure of nociceptive traﬃc
throughthedorsalhorn.C-foswasalsoreducedinnumerous
upstream brain structures demonstrating the importance of
blocking nociceptive traﬃc to prevent neuroplasticity [139].
Fedotozine also did not inﬂuence gastrointestinal transient
times. Fedotozine was ineﬀective in reducing symptoms
and gastroparesis in diabetic patients [140]. The kappa
receptor agonist ADL 10-0101 reduced pain in patients with
pancreatitis without inﬂuencing heart rate, respiratory rate,
oxygen saturation, or causing nausea. Analgesia appeared to
be mediated by receptors outside of the CNS [141]. Other
peripherally restricted kappa agonists are being developed
[142].
DAMGO and morphine are more potent in reduc-
ing acetic acid peritonitis in experimental animals when
given intracerebroventricular than intraperitoneal. Mor-
phine antinociception was only partially reversed by periph-
erally restricted mu receptor antagonists [143]. Methylnal-
trexone, a peripherally restricted mu receptor antagonist,
reverses dysmotility morphine and other mu opioid agonists
without reverse seen analgesia [144, 145]. Mu receptor6 Pain Research and Treatment
agonistssuchasfentanylarereportedtoreducevisceromotor
responses to colorectal distention in mice [146]. Neither
morphine, fentanyl, or delta agonists reduced the ﬁring ratio
of mesenteric aﬀerents, whereas kappa receptor agonists (U-
50,488 and fedotozine) did reduce ﬁring rate suggesting that
the opioid-induced sensitization occurs centrally and that
mu receptors are either absent on extrinsic spinal aﬀerents or
donotinﬂuenceactionpotentials[147].Theseﬁndingsagain
indicate that central and not peripheral mu receptors are
critical to modulating visceral pain; kappa agonists mediate
pain relief by binding to peripheral receptors.
There is evidence that fentanyl signiﬁcantly reduces
visceromotor responses to a greater extent when kappa
receptors are nonfunctional (kappa receptor gene “knocked-
out”mice)[148].Thecombinationoffentanylandthekappa
receptor agonist spiradoline produced dose-dependent
supra-additive antinociception in an animal model involv-
ing colorectal distention. However, there appears to be
a complex interplay between kappa and mu receptors.
Fentanyl nociception was not blocked, but the kappa agonist
antinociception was blocked by the mu receptor antagonist
(b-FNA) perhaps suggesting an interaction through dimers
[149]. There is little data about the beneﬁts of combining
kappa and mu receptor agonists in the clinical management
of visceral pain. A recent study of human volunteers found
that oxycodone which is thought to be a kappa and mu
receptor agonist signiﬁcantly blocked visceral pain better
than morphine which has little kappa receptor activity [150].
By speculation, a combination of a mu receptor agonist
and a peripherally restricted kappa receptor agonist might
selectively improve visceral pain relative to a peripherally
restricted kappa agonist or mu agonist alone.
3.6. Gamma Aminobutyric Acid Receptors. Gamma amino-
butyric acid receptor-B (GABA-B) is involved in modulating
mechanicosensory traﬃc through the vagus and brainstem
pathways.GABA-Breceptorsblockmechanico-sensoryinput
but do not modulate chemosensitivity. GABA-B agonists
directly inﬂuence sensory input via binding enteric receptors
or by way of activating inhibitory interneurons within the
CNS [151, 152]. Baclofen, a GABA-B receptor agonist, has
been used in animal models to test visceral nociception.
GABA-B receptors couple with N and P/Q calcium channels
and potassium channels which may be the mechanism
of antinociception. Activation of receptors downregulates
calcium channels and activates inward rectify potassium
channels which improves repolarization of neurons [153–
155]. Baclofen in male long Evans rats reduced aﬀerent ﬁring
fromacolorectaldistention.Thisoccursinadose-dependent
manner unrelated to smooth muscle relaxation or improved
colon compliance [156, 157]. Visceromotor responses from
colorectal distention are reduced by baclofen [157–159].
Baclofen also blocks the expression of c-fos in the dorsal
horn to experimental colitis and capsaicin-induced bladder
irritation [160, 161]. Baclofen reduced presynaptic release
of SP from visceral aﬀerents [162]. Volatile anesthetics
such as halothane, isoﬂurane, sevoﬂurane sevoﬂurane, and
propofol block visceral nociception via augmentation of
GABA-B [163, 164]. Baclofen in most clinical studies was
intrathecal, and the pain phenotype was largely neuropathic
[165–169]. Because baclofen crosses the blood-brain barrier,
beneﬁts may be mediated centrally. There is some evidence
for synergy between morphine and baclofen [166], but very
little clinical data are available about the use of baclofen for
visceral pain.
3.7. N-Methyl-D-Aspartate Receptors and ATP-Gated Ion
Channels. N-Methyl-D-aspartate(NMDA)receptorsarecal-
cium channels activated byglutamate and are slowlydesensi-
tizedonceactivated.Thesehigh-calciumpermeablechannels
generate synaptic neuroplasticity, wide dynamic range neu-
ronal responses, and gene expression within the CNS [170,
171]. NMDA receptor activation has been associated with
visceral hyperalgesia [170]. Due to slow inactivation, NMDA
receptors produce long-term potentiation (LTP) which gen-
erates chronic pain [172]. NMDA receptors are found on
enteric extrinsic aﬀerents from colon and bladder; these
aﬀerents release CGRP and SP once the receptor is activated
[173]. NMDA receptors are also found on postsynaptic,
second-order visceral aﬀerents, within the brainstem and
cortex [174–178]. Receptor activation by colon distention
does not require inﬂammation to be present which is
distinctly diﬀerent from somatic NMDA receptors [179–
181].Intravenousbutnotintrathecalmemantine(anNMDA
receptorblocker)reducedvisceromotorresponsestocolorec-
tal distention suggesting that peripheral NMDA receptors
areimportant to antinociception [173].TheNMDAreceptor
blocker, MK-801, prevented dorsal horn expression of c-
fos to noxious colorectal distention, and another NMDA
receptor blocker, APV, attenuated visceromotor responses to
graded colorectal distention in a dose-dependent manner
[173]. NMDA receptors within the RVM are important in
modulating pain [182].
There are 2 purinergic ion channels, P2X and P2Y. P2X
is an ATP-gated channel, and P2Y is a G-protein couple
receptor. ATP released by cell damage, from the sympathetic
nervous system or extrinsic sensory neurons, binds to P2X.
A subset of P2X channels (P2X3) were upregulated in
extrinsic aﬀerents neurons by inﬂammatory bowel disease
[183]. ATP released from the epithelial lining of the mucosa
binds to several subsets of P2X (P2X3 and P2X2/3) on
submucosal sensory neurons. In this way, P2X modulates
peristalsis [184–186]. P2X, upregulated by interleukin-1b,
was found to be a mechanism for postinfectious (jejunitis)
hypersensitivity in animal models. Animals not expressing
P2X subtype 7 on aﬀerents did not develop postjejunitis
visceral hypersensitivity [187].
3.8. Somatostatin and Bradykinin Receptors. Octreotide
blocks somatostatin-2 receptors (SST-2). Mesenteric aﬀerent
ﬁring rates caused by ramping jejunal pressures in Wistar
rats were blunted by octreotide [188]. Reduced ﬁring
rates occurred without change in small bowel compliance.
Octreotide also blocked bradykinin activation of mesenteric
aﬀerentsandimprovedsymptombehaviorsofirritablebowel
syndrome in animals [188–190]. Somatostatin inﬂuences
motility and increases gastrointestinal transit time [191].Pain Research and Treatment 7
Octreotide anecdotally reduced the abdominal pain of Men-
etrier’s disease and pain related to visceral cancer metastases
[192, 193]. Octreotide as an adjuvant to morphine reduced
pain in a cohort of individuals with gastrointestinal cancers
[194]. Octreotide relieved severe refractory epigastric pain in
individuals with weight loss and functional bowel disorders
[195]. Unfortunately, octreotide did not reduce pain from
pancreatitis [196].
Bradykinin activates mesenteric aﬀerents by way of B2
receptors and by stimulating prostaglandin production [197,
198]. The herbal preparation STW-5 (Ibergast Steigerwald
Gmb H, Darmstadt, Germany) dosedependently blocks
bradykinin-induced aﬀerents discharges from mesenteric
sensory neurons [199–201]. Ibergast was eﬀective in reduc-
ing symptoms from functional dyspepsia as reported in
a meta-analysis [202]. Ibergast also alters smooth muscle
contraction and motility [203, 204].
4. ProteinKinases
Protein kinase A phosphorylates NMDA receptor subunit
NR-1 and the transcription factor cyclic AMP (cAMP)
response element binding protein (CREB). CREB upreg-
ulates the receptor for SP (neurokinin-1 receptor) [205,
206]. Colonic distention induced protein kinase A phos-
phorylation of NMDA receptors in the second-order post-
synaptic dorsal column neurons. This was be blocked by
the NMDA receptor antagonist, CNQX [37]. In the same
manner, protein kinase C is upregulated in the gracile
nuclei and in postsynaptic dorsal column neurons with
visceral stimulation. Protein kinase C phosphorylates a
second glutamate receptor, AMPA [207]. Formalin-induced
colitis increased the activation of protein kinase C through
attachmenttoneuronalmembranesinthedorsalhorn[208].
The mitogenic activated protein kinase family of kinases
regulates neuron responses and neuroplasticity. Within this
family, the extracellular signaling-related kinases (ERK 1, 2)
are important to visceral pain. Activation of ERK has been
associated with visceral hyperalgesia [209]. ERKs couple to
multiple receptors including NMDA and neurokinin-1 [210,
211]. Increased expression ERK 1, 2 in the L6-S1 mouse
dorsal horn was associated with a leftward shift in viscero-
motorresponsestocolorectaldistention.Blockingthiskinase
attenuated visceromotor responses [212].
5. Pharmacologic Management of
Visceral Pain
Clinical trials of speciﬁc analgesics for visceral pain are
sparsely published. Visceral pain is included with somatic
and nociceptive pain in most clinical trials; as a result,
it is diﬃcult to determine the appropriate drug choices
for visceral pain as a phenotype. The fact that there are
some diﬀerences between somatic and visceral pain neu-
rotransmission, neurotransmitters, channels, and receptors
suggeststhattheremayinfactberealdiﬀerencesinresponses
to analgesics. The use of potent opioids for inﬂammatory
bowel disease has been associated with higher morbidity
and mortality which is not reported for various types of
somatic pain [213]. This may reﬂect the fact that patients on
opioids are sicker than those who are not but this may also
be related to the opioid. In a similar fashion, certain NSAIDs
have been associated with poorer outcomes in inﬂammatory
bowel disease but not for somatic pain [214, 215]. On
the other hand, octreotide improves colic and symptoms
from bowel obstruction better than anticholinergics; potent
opioids actually may worsen colic [216, 217].
It is unlikely that a single analgesic or targeted agent
will signiﬁcantly reduce most visceral pains since multiple
neurotransmitters, channels, and receptors are responsible
for visceral pain. Analgesics combinations are anticipated
to be better than single analgesics [218, 219]. Analgesics
which are ineﬀective as single agents or ineﬀective at a
particulardosemayhavesupra-additiveanalgesiaforvisceral
pain when combined with a second analgesic. Hence, single-
drug trials may not predict the merit of an analgesic supra-
additive analgesic combinations cannot be predicted based
onsingle-drugactivity.Analgesicdoseresponserelationships
for visceral pain may be distinctly diﬀerent from somatic
pain [220]. Opioids for somatic pain may in fact not work
well for visceral pain and visa versa. Kappa agonists may be
an example [150, 221].
Gastrointestinal motility has been assumed to be a
surrogate for gastrointestinal symptoms [222]. For instance,
it has been assumed that early satiety is related to reduced
gastric emptying or poor proximal gastric compliance.
However, kappa receptors improve satiety without chang-
ing gastrointestinal motility. Morphine and its metabolite,
morphine-6-glucuronide, reduce visceral pain but increase
circular muscle contraction, whereas somatostatin reduces
visceral pain and reduces smooth muscle contraction [223–
226]. TRPV1, Na 1.8, ASIC3 targeted analgesics, and kappa
receptor antagonists may have less adverse eﬀects on gas-
trointestinal motility than somatostatin or mu agonists
though future trials will need to conﬁrm this speculation.
Another point is that selective visceral blocks and proce-
dures (celiac, hypogastric, and splanchnic blocks, spinal cord
stimulators, radiofrequency ablation, and midline myelo-
tomy) needed to complement medical management [35,
227–229]. Multimodality approach for pain management
requires a multidisciplinary group of experts. There is a
tendency to overly rely on analgesics and refer individuals
to other disciplines late when pain is poorly controlled; the
cancer is widespread and patient tolerance to procedures is
poor [230].
There is little doubt that central sensitization plays a role
in maintaining visceral pain [79, 182, 231–233]. As a result,
uncontrolled acute visceral pain will likely lead to central
neuroplasticity and chronic pain despite the resolution of
underlying cause for pain. Certain analgesics will need to
penetrate the CNS to fully and eﬀectively relieve pain [182].
5.1. NSAIDs and Paracetamol. Paracetamol is a weak cy-
clooxygenase-2 inhibitor and a selective cyclooxygenase 3
inhibitor. It also increases brainstem serotonin neurotrans-
mission, redirects beta-endorphin, and inhibits 5-HT 3
receptors which are pronociceptive [234–237]. Paracetamol8 Pain Research and Treatment
is commonly used for pain, but little is known about visceral
pain responses since most studies have not focused on
visceral pain. In an acetic acid peritonitis model, com-
binations of ketoprofen plus paracetamol were synergistic
at a dose ratio of 3:1 (paracetamol to ketoprofen) [238].
Several other studies involving animal models of visceral
pain have conﬁrmed beneﬁts of NSAIDs plus paracetamol
combinations[239,240].Inaqualitativesystematicreviewof
paracetamol plus NSAIDs combinations, combinations were
superior to paracetamol alone in 85% and NSAIDs alone in
64% of studies. Ibuprofen was the most commonly used in
the 21 studies reviewed. Drug combinations reduced pain by
35% and analgesic supplemented by 38%. This combination
was superior in gynecology surgical studies (83%) indirectly
conﬁrming beneﬁts for visceral pain [241].
NSAIDs are eﬀective in reducing cancer pain in the
dose-dependent fashion [242]. However, a major systematic
review was not selectively focused on visceral pain [243].
Multiple studies have found that NSAIDs are eﬀective for
biliary colic and are as eﬀective as opioids with fewer side
eﬀects [244–247]. One of the mechanisms by which NSAIDs
work in renal or biliary colic may involve acetylcholine
blockade. Diclofenac blocks acetylcholine-induced smooth
muscle contraction [248]. NSAIDs were superior to anti-
cholinergics in relieving biliary colic with a number 3 needed
totreatandpreventedprogressiontocholecystitisbetterthan
anticholinergic with a number 3 needed to treat [249, 250].
In the same vein, NSAIDs are superior to anticholinergics
in relieving renal colic [251]. In a meta-analysis, NSAIDs
were superior to opioids in reducing renal colic [252]. Both
NSAIDsandopioidsprovideeﬀectiveanalgesiainacuterenal
colic, but opioids are associated with a higher incidence of
adverse events, particularly vomiting [252].
Nine percent of individuals with inﬂammatory bowel
disease treated with NSAIDs deteriorate clinically and im-
prove once the NSAID is discontinued. Loss of prostaglandin
by the NSAID leads to microvascular dysfunction and
sustained inﬂammation [215, 253, 254].
5.2. Opioids. Opioids reduce pain; however, poor coping
skills, depression, and catastrophization correlate better with
dose than the degree pathology [255, 256]. Opioids add a
symptom burden associated with dysmotility [19, 257, 258].
Proactive use of laxatives and bowel softeners are needed. In
addition, morphine can produce visceral hyperalgesia [124,
259] which is suppressed by gabapentinoids [260]. This may
explain the advantages of this combination when treating
visceral pain [219]. Features of hyperalgesia are increased
pain intensity extent of pain area, or radiation with reduced
responsiveness to opioid analgesia [261]. Opioid-induced
hyperalgesia mimics pain associated with progression of
the underlying pathological condition. Physicians unaware
of this phenomenon increase the opioid dose only to
worsen visceral pain. The addition of adjuvant analgesics
or opioid rotation is preferred in managing opioid-induced
hyperalgesia [262, 263]. Opioid functional selectivity occurs
in multiple downstream signaling pathways (beta arrestin 1
and 2, kinases, and G proteins) caused by unique opioid-
receptor conformation changes [264]. Functional selectivity
is also determined by expression of certain proteins within
the vicinity of the receptor. Opioid rotation will alter
downstream signaling and reset the analgesic response.
Paradoxically, opioid dose reduction may improve pain
control [265].
Sustained release oxycodone signiﬁcantly reduces chron-
ic cancer-related visceral pain. In a multicenter prospective
observational study involving 350 individuals with visceral
pain, oxycodone reduced pain severity from a mean of 7 to
a mean of 2.4 on a numerical rating scale (0 no pain, 10
severe pain) over a two-week period of time. Less than 5%
of individuals continued to have severe pain at the end of 2
weeks [266]. A small randomized trial found that morphine
was as eﬀective as oxycodone in relieving pain related to
pancreatic cancer [267]. Intranasal fentanyl was eﬀective in
managing acute visceral pain in the emergency department
[268]. At the present time, there is little published data to
give direction to the choice of opioids for visceral pain.
Combinations of analgesics which include opioids have
been reported in the management of visceral pain. In an
animal model, blocking TRPV1 enhanced opioid antinoci-
ception [269]. In a mouse model, the triple combination
of fentanyl, trazodone, and paracetamol reduced writhing
to acetic acid at doses lower than those seen with single
drugs [270]. In the rat colorectal distention model, ketorolac
alone was ineﬀective, and morphine modestly eﬀective but
the combination of ketorolac and morphine produced syn-
ergistic antinociception at dose ratios of 10:1 and 20:1 [271].
Combinationsoftramadolplusmorphineandtramadolplus
fentanyl produced synergistic antinociception in the acetic
acid writhe model but not with somatic pain (hot plate test)
[272].
5.3. Adjuvant Analgesics. There is preclinical and some
clinical evidence that adjuvant analgesics should be used
early for visceral pain. The combination of a gabapentinoid
plus opioid is a reasonable choice [109, 219]. Octreotide
reduces visceral hyperalgesia which is a logical choice to
use with morphine in malignant-related bowel obstruction
[189]. STW-5 blocks bradykinin receptors and pain from
jejunal distention and could potentially improve opioid
analgesia [200]. Baclofen reduces visceral nociception in
multiple models which makes it attractive to use with
opioids and nonopioid analgesics (NSAIDS or paracetamol)
[156]. NMDA receptor antagonists reduced visceral pain
in a diﬀerent manner advanced somatic pain and may
improve the opioid analgesia for visceral pain diﬀerently
than from somatic or neuropathic pain [173]. Combinations
of NSAIDs, paracetamol, and opioids are likely to be at
least additive if not synergistic [241]. Dexmedetomidine, an
alpha-2 antagonist, inhibited visceromotor responses to col-
orectaldistention[273].Inthesamemanner,tricyclicantide-
pressants and serotonin norepinephrine reuptake inhibitors
could improve visceral pain by increasing norepinephrine
neurotransmission. In addition, tricyclic antidepressants
inhibit sodium channels, NMDA receptors, P2X channels,
and prostaglandins [274]. Combinations of antidepressants
and opioids may improve visceral pain in a similar fashion
as the combination does for neuropathic pain. Overall, thePain Research and Treatment 9
clinical evidence for drug combinations is weak and requires
prospective clinical trials.
6. Summary
Visceral pain is mediated by unique peripheral and central
pathways. Several ion channels TRPV1, Na 1.8 and ASIC3,
andthekappaopioid receptorappearareparticularlyimpor-
tant to modulating pain. There are qualitative and quantita-
tive diﬀerences in pain processing from somatic pain such
that visceral pain should be considered a distinct phenotype.
Drug development and treatment paradigms have to take
this into consideration in cohort and randomized trials. This
has been done successfully for the irritable bowel syndrome.
Targeted agents are being developed to ion channels; it
is unlikely that these targeted agents will produce less
dysmotility than mu opioid receptor agonists. Ion channel
blockers are likely to have only a modest beneﬁt due to the
multiplicity of ion channels involved in visceral pain and will
have to be combined with other analgesics. There is evidence
that targeted agents for TRPV1 channels improve opioid
responses. Adjuvant analgesics such as the gabapentinoids
are eﬀective as single agents and should be considered early
in the course of opioid therapy to prevent opioid-induced
hyperalgesia and minimize opioid side eﬀects by being
“opioidsparing.”Peripherallyrestrictedkappaagonistsarein
development and should be combined with other analgesics
and adjuvants in hope of improving pain control. Interven-
tionalproceduresshouldbeconsideredearlytoavoidchronic
visceral pain poorly responsive to analgesics. Treatment
algorithms have been developed for neuropathic pain based
onmultiplerandomizedtrials.Thesameapproachshouldbe
taken in the management of visceral pain.
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